Exploring substrate–microbe interactions: a metabiotic approach toward developing targeted synbiotic compositions

Bodo Speckmann,Ellen Ehring,Jiaying Hu,Ana Rodriguez Mateos

DOI: https://doi.org/10.1080/19490976.2024.2305716

IF: 12.2

2024-02-03

Gut Microbes

Abstract:Gut microbiota is an important modulator of human health and contributes to high inter-individual variation in response to food and pharmaceutical ingredients. The clinical outcomes of interventions with prebiotics, probiotics, and synbiotics have been mixed and often unpredictable, arguing for novel approaches for developing microbiome-targeted therapeutics. Here, we review how the gut microbiota determines the fate of and individual responses to dietary and xenobiotic compounds via its immense metabolic potential. We highlight that microbial metabolites play a crucial role as targetable mediators in the microbiota-host health relationship. With this in mind, we expand the concept of synbiotics beyond prebiotics' role in facilitating growth and engraftment of probiotics, by focusing on microbial metabolism as a vital mode of action thereof. Consequently, we discuss synbiotic compositions that enable the guided metabolism of dietary or co-formulated ingredients by specific microbes leading to target molecules with beneficial functions. A workflow to develop novel synbiotics is presented, including the selection of promising target metabolites (e.g. equol, urolithin A, spermidine, indole-3 derivatives), identification of suitable substrates and producer strains applying bioinformatic tools, gut models, and eventually human trials. In conclusion, we propose that discovering and enabling specific substrate–microbe interactions is a valuable strategy to rationally design synbiotics that could establish a new category of hybrid nutra-/pharmaceuticals.

gastroenterology & hepatology,microbiology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to develop synbiotic formulations for specific health goals by studying substrate - microbe interactions. Specifically, the authors explored how the gut microbiome determines the fate of diet and xenobiotics and individual responses through its huge metabolic potential, emphasizing the crucial role of microbial metabolites as mediators in the microbiome - host health relationship. Based on these findings, they proposed an approach that goes beyond the traditional prebiotic promotion of probiotic growth and colonization, that is, by guiding the metabolism of specific microbes on diet or co - formulated components to produce target molecules with beneficial functions. This approach not only helps in designing new synbiotic products, but may also provide new ideas for developing novel nutrition/drug hybrid products.

The paper mentioned that the current clinical results of interventions using prebiotics, probiotics and synbiotics are mixed and difficult to predict, which has prompted researchers to explore new methods to develop microbiome - targeted therapies. By in - depth understanding of substrate - microbe interactions, synbiotics can be more rationally designed to achieve more precise health benefits. For example, by selecting appropriate substrates and production strains, and using bioinformatics tools, gut models and, ultimately, human trials, synbiotic combinations that can effectively produce target metabolites can be developed. These target metabolites include, but are not limited to, isoflavones, urolithin A, spermine and indole - 3 derivatives, etc., which have potential health benefits in cardiovascular health, inflammation regulation, antioxidant, etc.